
BioSpain breaking records
On its 20th anniversary in Catalonia’s vibrant capital Barcelona, BioSpain 2023 is set to break records in terms of attracting visitors,...

Breakthrough in microtia treatment
Researchers of the Tissue Engineering and Biofabrication Laboratory of the ETH Zurich unveiled a novel approach to addressing microtia, a congenital...

Memo Therapeutics AG raises CHF25m
The CHF25m Series C round of Schlieren-based Memo Therapeutics AG was led by Pureos Bioventures. Existing investors Swisscanto, Vesalius Biocapital,...

SeaBeLife secures €1.2m in funding
SeaBeLife SAS has secured €1.2m in funding, aiming to develop unique drug candidates that block cell necrosis and target two regulated cell death...

Novo Nordisk invests €2.1bn in production expansion
While Novo Nordisk’s main competitor Eli Lilly in the emerging market of effective drugs that fight obesity announced an investment of €11bn...

BioLamina AB bags €19m funding for expansion
The tenth investement from Lauxera Capital Partners through its Lauxera Growth I fund will be usesd by the Swedish company to expand the development...

Aboleris Pharma bags €27.3m in Series A Financing
AbolerIS Pharma SA’s financing was led by Caixa Capital Risc and co-led by Sound Bioventures and existing investor Newton Biocapital with...